- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life
The panel highlights the quality of life and emotional challenges faced by patients diagnosed with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
EP: 1.Overview of Characteristics Unique to Ph+ ALL
EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL
EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life
EP: 4.Screening and Diagnosing of Ph+ ALL in Adults
EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management
EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL
EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients
EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients
EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care
EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL
EP: 11.Disparities in Access to Care for Ph+ ALL patients
EP: 12.The Future of Ph+ ALL Treatments
EP: 13.Concluding Thoughts on Ph+ ALL Treatment
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Jonathon Abbas, MD; Vivian Tambe Tar, PharmD, MBA; Elias Jabbour, MD; and James McCloskey, MD.
The discussants focus on the impact of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and its treatment relating to patients' quality of life (QOL) and emotional well-being. Abbas noted the wide variation in patient age, from teenagers to octogenarians, each requiring personalized supportive care. The typically months-long treatment regimens with frequent clinic visits can be burdensome, especially for younger patients who may be building careers or families. Haumschild emphasized considering QOL goals, such as the ability to work and maintain mental health and relationships with loved ones. Monitoring QOL and adjusting care accordingly should be part of the treatment approach. The toxicity burden and its impact also require special attention in older patients with comorbidities. Overall, supporting patients with Ph+ ALL holistically emerges as a key priority.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Survey Explores Needs of Patients With DMD, BMD Transitioning to Adulthood
February 28th 2025Activities of daily life, education, and employment were areas of difficulty in the transition to adulthood for patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), but those who had more siblings reported being more ready to transition to adult life.
Read More
Falls, Balance Issues Signal Higher ICANS Risk in NHL
February 28th 2025Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Read More
